Fig. 3
Forest plot for primary outcomes and secondary outcomes. The forest plot was based on a random-effects model. The data behind the drug names indicate the following: Trials, number of trials examining the current active drug; Treatment/Placebo, number of patients with events/number of patients in which the drug was examined in these trials; OR, odds ratio; CI, credible interval. 95% CI that did not contain one and a p-value cutoff point of 0.05 was considered statistically significant. I2 values of less than 50% indicate that heterogeneity may not be significant; a value higher than 50% may represent substantial heterogeneity. For the effectiveness endpoint, results to the left of 1 favor placebo, to the right favor intervention, result in adverse events was the opposite. DFN-02, sumatriptan nose spray 10 mg with a permeation enhancer; AVP-825, a drug-device combination of 22mg sumatriptan powder; MAP0004, a dihydroergotamine inhaler; ROX-828, ketorolac 31.5mg with 6% of lidocaine